Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4 / lymphocyte count. The effect of combination protease inhibitor therapy (ritonavir plus saquinavir) on functional measures of cell-mediated immunity in 41 HIV-infected patients from one center of a multicenter trial was investigated. After 24 weeks, median plasma virus load decreased from 4.74 log 10 copies/mL to below the detection limit of the assay (2.30 log 10 ), and mean CD4 / lymphocyte count increased from 284 cells/mL to 413 cells/mL. Proliferative responses to phytohemagglutinin developed in 21 of 34 patients in whom responses were absent at baseline. Increases were observed in interleukin-2, -12, and -10 production and in the expression of CD28 on CD8 / lymphocytes. Initiation of potent anti-HIV therapy results in a degree of immune restoration, suggesting that HIV-induced immune suppression is a dynamic and potentially reversible process.
Progressive loss of cell-mediated immunity (CMI) is the [7 -9] . Progression of HIV disease appears to be associated with decreased production of IL-12 [10 -12] and an overexhallmark of human immunodeficiency virus (HIV) disease and is responsible for the ultimate development of serious opportupression of IL-10 [13], and the impaired proliferative capacity of PBMC from HIV-infected persons can be restored in vitro nistic infections and malignancies. Although the CD4 / T cell count is useful in the prognosis and therapy of HIV-infected by the addition of IL-12 or anti -IL-10 antibodies [12 -16] . This suggests that a reversible loss of CMI exists in HIVpersons, it is an imperfect measure of cellular immune function. Cell-mediated immune dysfunction, as determined by impaired infected persons and is, at least in part, due to dysregulation of IL-12 and IL-10 production. peripheral blood mononuclear cell (PBMC) proliferation or interleukin (IL)-2 production, can be detected early in the Optimal T cell function requires the interaction of the T cell receptor with the major histocompatibility complex -peptide course of HIV infection [1 -4] and provides prognostic information independent of CD4 / T cell number [5, 6] . Restoration complex on the antigen-presenting cell (APC) in association with a costimulatory signal. This costimulatory signal involves of cell-mediated immune responses may, therefore, be of considerable benefit to HIV-infected patients.
the interaction of the B7 molecule on the APC with the CD28 molecule, which is expressed on the surface of Ç95% of CD4
/
In addition to PBMC proliferation and IL-2 production, CMI T cells and 50% of CD8 / T cells in peripheral blood of HIVcan be evaluated by a number of other measures. Generation seronegative persons [17 -20] . Decreased CD28 expression on of cell-mediated immune responses is associated with the pro-CD8 / T cells, and to a lesser degree on CD4 / T cells, has duction of IL-12, whereas IL-10 down-regulates such responses been shown to be associated with progression of HIV disease [21 -24] and is felt to be another indicator of impaired CMI. Along with their ability to decrease virus load, improve tion that increases saquinavir bioavailability and have largely final dilution, 1:10,000) and incubated at 37ЊC and 5% CO 2 . After nonoverlapping viral resistance patterns [31, 32] . This has 24 h, cells were pelleted, and supernatants were collected and given us an opportunity to study the effect of this potent antiretfrozen at 070ЊC. After week 24, samples were processed, and roviral therapy on several aspects of immune function in a supernatants from all time points were thawed and assayed for relatively large number of patients.
IL-2 (BioSource International, Camarillo, CA), IL-12 p40 (Biosource), and IL-12 p70 (R&D Systems, Minneapolis) by a commercially available ELISA. IL-10 was measured by an established sandwich ELISA as previously described [33] . / lymphocyte counts. At frequent inwas distributed into 12 1 75 polypropylene tubes (Sarstedt, Newtervals, including baseline, week 4, and week 24, blood was colton, NC) containing saturating amounts (5 mL) of phycoerythrinlected in an acid citrate dextrose-containing tube, and plasma conjugated mouse anti-CD4 antibody (Sigma) or phycoerythrinwas immediately separated and transported to a central laboratory conjugated mouse anti-CD8 antibody (Becton Dickinson, Lincoln / and cells/mL in endotoxin-free RPMI 1640 with 5% pooled HIV-sero-CD8 / cells that expressed CD28 were determined. negative AB serum from a single lot (Advanced Biotechnologies, Data analysis. Data are presented as mean { SD if normally Columbia, MD). Proliferation assays were performed as previously distributed; otherwise, they are presented as median and interdescribed [1] . Cell suspension was aliquoted (100 mL) into 96-quartile range (IQR). Cytokine production at the three time points well plates (Falcon, Lincoln Park, NJ) and stimulated in triplicate was compared using a Kruskal-Wallis test with pairwise compariwith HIV p24 antigen (Chiron Biomaterials, Emeryville, CA; final sons of on-treatment versus baseline levels (Dunnett test). Develconcentration, 1 mg/mL) or phytohemagglutinin-M (PHA; Gibco opment of or improvement in proliferative responses and changes BRL, Grand Island, NY; final dilution, 1:200). After 6 days of in cytokine production were correlated with changes in virus load incubation at 37ЊC and 5% CO 2 , cells were pulsed with 1 mCi of and CD4 / lymphocyte count using Spearman's correlation. 1:200, for 6 days). In addition, the median cpm of the ''responders'' at baseline were considerably lower than values at 0 -11.5%) subjects proliferated (SI ú3) in response to p24 antigen. This increased to 9 (22.0%; 95% CI, 9.3% -34.6%) 4 and 24 weeks, suggesting that although proliferative responses may have been present prior to therapy, such responses after 4 weeks and 10 (24.4%; 95% CI, 11.2% -37.5%) after 24 weeks (figure 1). Median cpm in unstimulated PBMC was were much more pronounced while patients were receiving ritonavir plus saquinavir. Thirty of the 34 patients who were 191 (IQR, 93 -598). In patients who exhibited proliferative responses to p24 antigen, the median cpm were 937 (IQR, initially unresponsive to PHA at baseline developed proliferative responses, while 3 of the 7 patients who were initially 782 -1091; n Å 2), 917 (IQR, 290 -1257; n Å 9), and 2360 (IQR, 1748 -2800; n Å 10) at weeks 0, 4, and 24, respectively.
responsive at baseline exhibited an increase (ú2.5-fold increase in SI) in their proliferative response at either 4 or 24 In patients who did not exhibit a proliferative response to PHA, median cpm were 104 (IQR, 75 -161; n Å 39), 232 (IQR, weeks. Of patients with proliferative responses to PHA at baseline, 4 became unresponsive at 24 weeks of therapy. Eight 91 -978; n Å 32), and 795 (IQR, 329 -990; n Å 31). Of the 39 patients who were initially unresponsive to p24 antigen, 17 patients initially unresponsive to PHA, who developed a proliferative response at 4 weeks, subsequently became unresponsive developed a proliferative response at either 4 or 24 weeks. Of patients with proliferative responses to p24 antigen at baseline, at 24 weeks. Changes in proliferative responses did not correlate with baseline values or quantitative changes in either virus both became unresponsive by 24 weeks of therapy. Seven patients initially unresponsive to p24 antigen, who developed a load or CD4 / lymphocyte count. Cytokine production. To further assess T cell function, IL-2 proliferative response at 4 weeks, subsequently became unresponsive at 24 weeks.
production in response to stimulation with PHA was measured. PHA-stimulated PBMC produced a median of 268 (IQR, In response to PHA, PBMC of 7 (17.1%; 95% CI, 5.6% -28.6%) subjects proliferated at baseline. The number of pa-105 -803) pg/mL IL-2 at baseline. This increased to 716 (IQR, 302 -1247) pg/mL at week 24 (P õ .05 for week 24 vs. week tients whose PBMC proliferated in response to PHA increased to 26 (63.4%; 95% CI, 48.7% -78.2%) after 4 weeks and 25 0; n Å 41; table 1). In order to determine the effect of potent antiretroviral thernificantly increased at 24 weeks (46%) versus baseline (32%; P õ .05 for week 24 vs. week 0; n Å 13), whereas there was apy on APC function and, in particular, APC function required for the generation of CMI, IL-12 production in response to no change in CD28 expression on CD4 / lymphocytes. Impact of discontinuation of therapy on immune function. LPS or SAC stimulation was evaluated. LPS-stimulated PBMC produced a median of 543 (IQR, 276 -1006) pg/mL IL-12 p40
Of interest is the anecdotal observation of 1 patient who, after being compliant for 24 weeks, discontinued therapy at week at baseline. This increased to 718 (IQR, 400 -1475) pg/mL at week 4 and 949 (IQR, 373 -1799) pg/mL at week 24 (P õ . 05 26. This case was unique in that this was the only patient to entirely discontinue antiretroviral therapy. His PBMC were for 4 weeks vs. baseline and 24 weeks vs. baseline; n Å 41; table 1). There was, however, no change observed in median initially unresponsive to both p24 antigen and PHA. At 4 weeks of therapy, his plasma HIV RNA level was below the detection SAC-induced IL-12 p40 production. Both SAC-and LPS-induced IL-12 p70, the biologically active heterodimer, were limit of the assay, and he developed a proliferative response to PHA. At 24 weeks, his plasma HIV RNA level remained undetectable at all time points in virtually all patients assayed.
IL-10 is produced by both T cells and APCs and inhibits below the detection limit of the assay, and he developed a proliferative response to p24 antigen. Two weeks after disconthe generation of cellular immune responses [8, 9] . The effects of PHA, a T cell mitogen, and LPS, a potent inducer of monotinuing his medication because of gastrointestinal intolerance, his plasma HIV RNA level rebounded to 98,600 copies/mL cyte-derived cytokines, on IL-10 production were therefore studied. PHA-stimulated PBMC produced a median of 258 and his proliferative response to p24 antigen was lost. Four weeks later (week 32), prior to restarting antiretroviral therapy, (IQR, 78 -407) pg/mL IL-10 at baseline. This increased to 635 (IQR, 238 -1194) pg/mL at week 4 and 1510 (IQR, 715 -2975) his proliferative response to PHA was also lost (figure 2). pg/mL at week 24 (P õ .05 for week 4 vs. week 0 and week 24 vs. week 0; n Å 41; table 1). LPS-induced IL-10 production Discussion was 1193 (IQR, 488 -2611) pg/mL at baseline and increased to 4024 (IQR, 1494 -13,550) pg/mL at 24 weeks (P õ .05 for
We demonstrate that, in the population studied, initiation of week 24 vs. week 0; n Å 41; table 1).
therapy with potent antiretroviral activity is paralleled by a No changes in cytokine production were found to correlate rapid and sustained improvement in a number of functional with baseline values or quantitative changes in either virus load measures of CMI. Treatment-induced changes were observed or CD4
/ lymphocyte count. CD28 expression. Optimal T cell function requires T cell -APC interactions, which include signals mediated through CD28, a costimulatory molecule present on T cells [19, 20] .
CD28 (mean { SD, n Å 13).
Since expression of CD28 is down-regulated in HIV infection [21 -24] , it was anticipated that decreasing plasma viremia would lead to and increased IL-2 production) may ultimately contribute to improved clinical outcomes. The majority of patients developed increased IL-12 production. In fact, LPS-induced IL-12 p40 production increased after 4 weeks and further increased after proliferative responses to PHA at 4 weeks and sustained this at 24 weeks (14 patients), first developed a proliferative re-24 weeks of therapy. The reason that there was an increase in LPS-but not SAC-induced IL-12 p40 production is not clear. sponse to PHA at 24 weeks (8 patients), or exhibited, at 24 weeks, an increase from their initial proliferative response to
The mechanisms by which these compounds induce cytokine production differ, and it is possible that decreasing HIV replica-PHA (2 patients). Although the number of patients with proliferative responses to p24 antigen was greater at both 4 and 24 tion by protease inhibition over a period of 6 months reverses HIV-induced abnormalities of LPS signaling but not of SAC weeks than at baseline, this was less impressive than the response to PHA, and many responses appeared to be transient.
signaling. Since proliferative responses to recall antigen are lost prior to
The observation that both SAC-and LPS-induced IL-12 p70 those in response to mitogen [1] , it is logical that PHA-induced were undetectable in virtually all patients is consistent with proliferation would be restored prior to p24 antigen-induced published observations [11] and may not exclude an increase proliferation. The reason that some patients exhibited transient in IL-12 bioactivity. Since an increase in IL-12 p40 is felt to improvements in proliferative responses, despite optimal viroreflect an increase in in vivo IL-12 bioactivity [35] , the increase logic responses, is unclear.
in LPS-induced IL-12 p40 observed here may represent improvement in monocyte/macrophage function, further contribAfter 24 weeks of potent antiretroviral therapy, the percentuting to improved cellular immune responses. Since the addiage of CD8 / lymphocytes expressing CD28 increased from tion of exogenous IL-12 to PBMC from HIV-seropositive 32% to 46%, similar to the level of expression in HIV-seronegpersons restores their proliferative capacity in response to antiative persons [21, 23] . Since IL-2 production and proliferation gen or mitogen [14 -16], the improvement in PBMC proliferaare impaired in CD280, as compared to CD28 /
CD8
/ lymphotive responses after 4 and 24 weeks of therapy is consistent cytes [21, 34] , an increase in the percentage of CD8 / lymphowith an increase in IL-12 bioactivity. cytes expressing CD28 at 4 weeks and a further increase at 24 weeks may be another indication of a continuous improvement IL-10 plays a complex and likely vital role in HIV immunopathogenesis. Although IL-10 may inhibit cellular immune rein T cell function. Whether an increase in the proportion of CD8 / T cells expressing CD28 leads to improved CTL activity sponses, some investigators have observed decreased produc-
